Advertisement

Document › Details
BioMed X GmbH. (1/14/25). "Press Release: BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy". Heidelberg.
![]() |
Region | Heidelberg |
Country | Germany | |
![]() |
Organisation | BioMed X GmbH |
Organisation 2 | Daiichi Sankyo Co., Ltd. (TSE: 4568.JP) | |
Group | Daiichi Sankyo (Group) | |
![]() |
Product | cancer drug |
Product 2 | trispecific antibody | |
![]() |
Person | Tidona, Christian (BioRN Cluster Management GmbH 201109 Managing Director) |
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors.
BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new project, entitled “New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumors)”, will be hosted at the BioMed X Institute in Heidelberg.
The goal of this partnership is to leverage the latest advances in multi-functional biologics, such as bi- and tri-specific antibodies, to develop new therapies that can engage multiple targets simultaneously within the tumor microenvironment. These next-generation therapies aim to overcome the limitations of conventional treatments by leveraging synergistic effects of different antitumor signaling pathways and mechanisms by manipulating proximity of multiple targets.
Call for Research Proposals
The BioMed X Institute and Daiichi Sankyo are inviting proposals from researchers around the world to participate in this ambitious project.
The MTT initiative focuses on the following key research challenges:
> Development of new therapeutic concepts for bi- or multi-specific biologics for new extracellular or intracellular target combinations which could be exploited for the treatment of solid tumors.
> Exploration, identification, and functional validation of promising new target combinations in vitro and in vivo.
> Development of an elegant in vitro assay system for functional assessment of novel target combinations.
Researchers are encouraged to submit proposals that demonstrate originality, especially those supported by preliminary experimental data or utilizing state-of-the-art machine learning tools. The call is open to projects targeting any solid tumor indication. However, classical immune cell engagers, combination therapies, and other modalities outside peptides or proteins (e.g., small molecules, nucleic acids, gene or cell therapies) are not within the scope of this project.
The new research team will join seven other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2025-BMX-C01 before March 9, 2025.
Christian Tidona, Founder and Managing Director of the BioMed X Institute, commented: “Partnering with Daiichi Sankyo on the MTT project allows us to expand our research in oncology, focusing on next-generation biologics that can truly make a difference for cancer patients. This collaboration exemplifies our commitment to pioneering innovative therapeutic approaches.”
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
Press Contact
Maria Morganti
Head of Marketing
[email protected]
+49 6221 426 11 29
Record changed: 2025-01-21 |
Advertisement

More documents for BioMed X GmbH
- [1] Aion Labs. (10/19/21). "Press Release: Aion Labs, Powered by BioMed X, Launches First Global Call for Application – Artificial Intelligence for Antibody Design". Rehovot & Heidelberg....
- [2] Aion Labs. (10/13/21). "Press Release: Aion Labs, Biotech Innovation Lab Launched by Top Pharma, Tech and Investment Leaders". Rehovot....
- [3] BioMed X GmbH. (2/14/19). "Press Release: Merck and BioMed X Expand Collaboration to Immunology Research". Heidelberg....
- [4] BioMed X GmbH. (1/17/19). "Press Release: BioMed X and Boehringer Ingelheim to Investigate Early Intervention in Psychiatric Diseases". Heidelberg....
- [5] BioMed X GmbH. (1/7/19). "Press Release: Velabs Therapeutics to Cooperate with BioMed X in the Field of Immunology". Heidelberg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top